Brief: Molecure Announces First Patient Dosed In Phase I Trial With Novel, First-In-Class Dual Arginase Inhibitor OATD-02

Molecure SA

08/03/2023 17:54

March 8 (Reuters) - Molecure SA  MOCP.WA :
    * MOLECURE ANNOUNCES FIRST PATIENT DOSED IN PHASE I TRIAL
WITH
NOVEL, FIRST-IN-CLASS DUAL ARGINASE INHIBITOR OATD-02 FOR THE
TREATMENT OF CANCER
    * MOLECURE SA - STUDY IS BEING CONDUCTED AT THREE SITES IN
POLAND
AND WILL ENROLL A MAXIMUM OF 40 PATIENTS
    * MOLECURE SA - INITIAL DATA FROM THIS FIRST IN HUMAN STUDY
IN
LATTER PART OF 2023
    * MOLECURE SA - SECOND NEW DRUG CANDIDATE FROM MOLECURE'S
PROPRIETARY PIPELINE IN CLINICAL DEVELOPMENT

Source text for Eikon:  ID:nGNX5RjPf7 
Further company coverage:  MOCP.WA 

 ((Reuters.Briefs@thomsonreuters.com;))